ESSA Pharma Inc (EPIX) Fundamental Analysis & Valuation

NASDAQ:EPIX • CA29668H7085

Current stock price

0.2012 USD
0 (-1.85%)
At close:
0.1951 USD
-0.01 (-3.03%)
After Hours:

This EPIX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. EPIX Profitability Analysis

1.1 Basic Checks

  • In the past year EPIX has reported negative net income.
  • EPIX had a negative operating cash flow in the past year.
  • EPIX had negative earnings in each of the past 5 years.
  • EPIX had a negative operating cash flow in each of the past 5 years.
EPIX Yearly Net Income VS EBIT VS OCF VS FCFEPIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • EPIX has a better Return On Assets (-22.73%) than 74.58% of its industry peers.
  • The Return On Equity of EPIX (-23.07%) is better than 82.43% of its industry peers.
Industry RankSector Rank
ROA -22.73%
ROE -23.07%
ROIC N/A
ROA(3y)-20.28%
ROA(5y)-21.7%
ROE(3y)-20.7%
ROE(5y)-22.14%
ROIC(3y)N/A
ROIC(5y)N/A
EPIX Yearly ROA, ROE, ROICEPIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EPIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPIX Yearly Profit, Operating, Gross MarginsEPIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. EPIX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for EPIX has been reduced compared to 1 year ago.
  • The number of shares outstanding for EPIX has been increased compared to 5 years ago.
  • EPIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EPIX Yearly Shares OutstandingEPIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
EPIX Yearly Total Debt VS Total AssetsEPIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • EPIX has an Altman-Z score of 0.99. This is a bad value and indicates that EPIX is not financially healthy and even has some risk of bankruptcy.
  • EPIX has a Altman-Z score of 0.99. This is in the better half of the industry: EPIX outperforms 61.50% of its industry peers.
  • There is no outstanding debt for EPIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.99
ROIC/WACCN/A
WACCN/A
EPIX Yearly LT Debt VS Equity VS FCFEPIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 69.06 indicates that EPIX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 69.06, EPIX belongs to the best of the industry, outperforming 99.63% of the companies in the same industry.
  • EPIX has a Quick Ratio of 69.06. This indicates that EPIX is financially healthy and has no problem in meeting its short term obligations.
  • EPIX's Quick ratio of 69.06 is amongst the best of the industry. EPIX outperforms 99.63% of its industry peers.
Industry RankSector Rank
Current Ratio 69.06
Quick Ratio 69.06
EPIX Yearly Current Assets VS Current LiabilitesEPIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. EPIX Growth Analysis

3.1 Past

  • EPIX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.67%.
EPS 1Y (TTM)-6.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, EPIX will show a very strong growth in Earnings Per Share. The EPS will grow by 72.82% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.16%
EPS Next 2Y30.89%
EPS Next 3Y6.83%
EPS Next 5Y72.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPIX Yearly Revenue VS EstimatesEPIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2029 2030 2031 2032 200M 400M 600M 800M
EPIX Yearly EPS VS EstimatesEPIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. EPIX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EPIX. In the last year negative earnings were reported.
  • Also next year EPIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPIX Price Earnings VS Forward Price EarningsEPIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPIX Per share dataEPIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.89%
EPS Next 3Y6.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EPIX Dividend Analysis

5.1 Amount

  • EPIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

EPIX Fundamentals: All Metrics, Ratios and Statistics

ESSA Pharma Inc

NASDAQ:EPIX (10/8/2025, 8:00:02 PM)

After market: 0.1951 -0.01 (-3.03%)

0.2012

0 (-1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06
Earnings (Next)12-15
Inst Owners73.7%
Inst Owner Change0%
Ins Owners2.08%
Ins Owner Change-160179%
Market Cap9.52M
Revenue(TTM)N/A
Net Income(TTM)-25.12M
Analysts45.71
Price Target1.73 (759.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.09
P/tB 0.09
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS2.3
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.73%
ROE -23.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.28%
ROA(5y)-21.7%
ROE(3y)-20.7%
ROE(5y)-22.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 69.06
Quick Ratio 69.06
Altman-Z 0.99
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.72%
EPS Next Y-13.16%
EPS Next 2Y30.89%
EPS Next 3Y6.83%
EPS Next 5Y72.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.01%
OCF growth 3YN/A
OCF growth 5YN/A

ESSA Pharma Inc / EPIX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ESSA Pharma Inc (EPIX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to EPIX.


What is the valuation status for EPIX stock?

ChartMill assigns a valuation rating of 0 / 10 to ESSA Pharma Inc (EPIX). This can be considered as Overvalued.


Can you provide the profitability details for ESSA Pharma Inc?

ESSA Pharma Inc (EPIX) has a profitability rating of 1 / 10.


Can you provide the financial health for EPIX stock?

The financial health rating of ESSA Pharma Inc (EPIX) is 8 / 10.


What is the earnings growth outlook for ESSA Pharma Inc?

The Earnings per Share (EPS) of ESSA Pharma Inc (EPIX) is expected to decline by -13.16% in the next year.